Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECT study of individualized dasatinib dosing in chronic-phase chronic myelogenous leukemia
ACTRN12616000738426Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic myelogenous leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Cumulative incidence of pleural effusion. Started Dec 2016; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12616000738426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000738426.